Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Blinded, Placebo-Controlled Extension to Study TRCA-301 to Evaluate the Long-term Safety and Durability of Effect of TRC101 in Subjects with Chronic Kidney Disease and Metabolic Acidosis

Next Previous
X
Search
Trial Profile

A Blinded, Placebo-Controlled Extension to Study TRCA-301 to Evaluate the Long-term Safety and Durability of Effect of TRC101 in Subjects with Chronic Kidney Disease and Metabolic Acidosis

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 22 Dec 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Veverimer (Primary)
  • Indications Metabolic acidosis; Renal failure
  • Focus Adverse reactions; Registrational
  • Sponsors Tricida

    • Most Recent Events

    • 07 Jul 2021 Results of post hoc subgroup analysis evaluated effects of veverimer on metabolic acidosis and physical function among patients with diabetes published in the Nephrology Dialysis Transplantation
    • 10 Feb 2021 According to a Zhang Investor Law media release, a class action lawsuit has been filled on behalf of shareholders of Tricida. According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that, Tricida's NDA for veverimer was materially deficient; accordingly, it was foreseeably likely that the FDA would not accept the NDA for veverimer; and hence, the Company's public statements were materially false and misleading.
    • 08 Dec 2020 'According to a Tricida media release, if accepted for consideration, a decision on the FDRR is expected in the first quarter of 2021. The timing and next steps for a resubmission of the NDA for veverimer will be dependent upon the OND's decision.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top